Plain language summary
======================

Bronchiectasis is characterized by recurrent airway infection and inflammation. The association of atherosclerosis and inflammation is well established. However, studies on the relationship between bronchiectasis and stroke are scant. Therefore, we conducted a population-based cohort study to determine the incidence and risk of ischemic stroke in patients with bronchiectasis.

The patients with bronchiectasis exhibited a higher incidence rate of ischemic stroke (9.18 vs 4.66 per 1,000 person-years) than the patients without bronchiectasis, with an adjusted hazard ratio (aHR) of 1.74 (95% confidence interval \[CI\] =1.28--2.35). The patients with bronchiectasis carried a dose response of ischemic stroke according to the number of emergency visits and hospitalizations per year.

This study indicated that bronchiectasis is an independent risk factor of ischemic stroke. Clinicians should take proactive strategies to carefully assess risk factors of stroke, and holistically treat patients with bronchiectasis.

Introduction
============

Bronchiectasis is characterized by a permanent dilatation and thickening of the bronchial tree caused by recurrent airway infection and inflammation. Common symptoms of bronchiectasis include viscid sputum production, hemoptysis, dyspnea, and weight loss.[@b1-copd-12-1375],[@b2-copd-12-1375] High-resolution computed tomography (HRCT) is the recognized gold standard for the diagnosis of bronchiectasis.[@b3-copd-12-1375],[@b4-copd-12-1375]

Bronchiectasis can cause substantial impact not only on patients' physical and psychosocial well-being but also on morbidity and mortality.[@b2-copd-12-1375],[@b5-copd-12-1375] A recent study from the United Kingdom reported an association between bronchiectasis and increased prevalence of coronary heart disease and stroke.[@b6-copd-12-1375] The probable pathology is that leukocyte recruitment and inflammatory mediators may activate atherogenesis.[@b7-copd-12-1375],[@b8-copd-12-1375] Libby reported that leukocyte recruitment and expression of proinflammatory cytokines characterize early atherogenesis and that malfunction of inflammatory mediators mutes atheroma formation in mice.[@b7-copd-12-1375],[@b8-copd-12-1375] It was also observed that autoimmune diseases such as rheumatoid arthritis, a chronic systemic inflammation, predispose to atherosclerosis and cardiovascular disease.[@b7-copd-12-1375],[@b8-copd-12-1375] Systemic inflammation can increase intima medial thickness in carotid artery and the presence of carotid plaque.[@b9-copd-12-1375],[@b10-copd-12-1375] Hence, patients who have bronchiectasis and experience frequent respiratory infections may have an increased risk of ischemic stroke.

Stroke is the rapid development of a focal neurologic deficit caused by a disruption of blood supply to the corresponding area of brain. It can lead to the most devastating impairment of physical and physiological function and therefore result in a great social and economic burden worldwide.[@b11-copd-12-1375] In addition, stroke remains the second leading cause of death in the world and in Taiwan as well.[@b12-copd-12-1375]--[@b14-copd-12-1375] Medical comorbid disorders, such as hypertension, diabetes, hyperlipidemia, coronary artery disease (CAD), congestive heart disease (CHF), and atrial fibrillation (AF), are well-established risk factors of stroke.[@b15-copd-12-1375]--[@b19-copd-12-1375] Recent studies have indicated that chronic obstructive pulmonary disease (COPD) is also associated with an increased risk of stroke.[@b20-copd-12-1375],[@b21-copd-12-1375] However, studies on the relationship between bronchiectasis and stroke for an Asian population are scant. Therefore, in this study, we conducted a nationwide population-based cohort study to evaluate the incidence and risk of ischemic stroke in patients with bronchiectasis in Taiwan.

Methods
=======

Data source
-----------

Single-payer National Health Insurance (NHI) program started from March 1, 1995, in Taiwan. More than 99.9% of Taiwan's citizens have been enrolled in this program in 2015.[@b22-copd-12-1375] The National Health Insurance Research Database (NHIRD) was provided by the National Health Insurance Administration (NHIA, formerly named Bureau of National Health Insurance) and managed by the National Health Research Institute. We used the Longitudinal Health Insurance Database (LHID), a sub-database of NHIRD, comprising data of 1 million randomly selected beneficiaries of the NHI program in 2000. The database has been released for public research after deidentification of the beneficiaries. A variety of outpatient and inpatient medical records are included in the LHID. Diagnoses are coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Previous studies have validated the diagnosis of ICD-9-CM codes in the database.[@b23-copd-12-1375]--[@b25-copd-12-1375] This study was approved by the Institutional Review Board of Tsaotun Psychiatric Center, Ministry of Health and Welfare (IRB No 105002). The National Health Research Institute de-identified the study participants before NHIRD release for public research. Therefore, the Institutional Review Board waived the requirement for patient written informed consent for this study.

Study patients
--------------

The patients with bronchiectasis (ICD-9-CM Code 494) newly confirmed by HRCT examination and with age ranging from 20 to 90 years visiting health care centers (outpatients or inpatients) within 2000--2008 constituted a bronchiectasis cohort. The date of bronchiectasis first diagnosed was used as the index year. The comparison cohort consisted of patients without bronchiectasis randomly selected from general population and 5:1 ratio frequency-matched with bronchiectasis cohort according to sex, age, and index year. Patients with ischemic stroke (ICD-9-CM Code 433-435) diagnosed before the index date were excluded in both cohorts.

Outcome measures
----------------

The outcome variable was ischemic stroke (ICD-9-CM Code 433-435) diagnosed and confirmed by CT or magnetic resonance image (MRI) examinations. CT or MRI is widely used to distinguish ischemic stroke from hemorrhagic stroke. The follow-up person-years (PYs) were calculated based on the interval between the index date and the date the ischemic stroke event first occurred or was censored: withdrawal from the NHI program, death, or the end of 2010 when the study terminated.

Covariates and comorbid diseases
--------------------------------

The patients were divided into the three groups according to age: age \<50 years as young adults, age 50--64 years as middle-aged adults, and age ≥65 years as elderly adults. The comorbid diseases reported to be risk factors of stroke, including hypertension (ICD-9-CM codes 401-405); diabetes (ICD-9-CM codes 250); hyperlipidemia (ICD-9-CM codes 272); CAD (ICD-9-CM codes 410-414) including myocardial infarction (ICD-9-CM codes 410 and 412), ischemic heart disease (ICD-9-CM codes 411 and 414), and angina pectoris (ICD-9-CM code 413); CHF (ICD-9-CM 428); COPD (ICD-9-CM 491, 492, 496); and AF (ICD-9-CM 427.31) were considered in this study.[@b15-copd-12-1375]--[@b19-copd-12-1375]

Statistical analyses
--------------------

The Statistical Package for the Social Sciences (SPSS) Version 22.0 (IBM Corp., Armonk, NY, USA) was adopted for all statistical analyses. The *χ*^2^ test was used to compare and test difference in the proportional distribution of the demographic characteristics and comorbidities in both cohorts. The Student's two sample *t*-test was used to measure and compare the mean ages of both cohorts. We evaluated the overall, age-specific, and comorbidity-specific incidence of ischemic stroke in both cohorts by follow-up PYs. Cox proportional hazard regression models were used to compare the hazard ratio (HR) and 95% CI of ischemic stroke development between patients with bronchiectasis and those without bronchiectasis. Nelson--Aalen analysis was adopted to evaluate the difference of cumulated probability of ischemic stroke between the two cohorts using XLSTAT add-on statistic software (Addinsoft Inc., Chicago, IL, USA). The significance level was set at *P*\<0.05 at 2-tail.

Results
=======

Demographic characteristics and comorbidities of patients with and without bronchiectasis
-----------------------------------------------------------------------------------------

A total of 7,770 patients, including 1,295 patients with bronchiectasis (585 men and 710 women) and 6,475 patients without bronchiectasis (2,925 men and 3,550 women), have 6,312.70 and 34,958.00 follow-up PYs, respectively. The age and sex distribution of the patients in both cohorts were the same. The mean age of the patients in both cohorts was 62.0±15.3 years. The bronchiectasis cohort exhibited a significantly higher prevalence of CAD (16.8% vs 13.1%), CHF (8.0% vs 2.8%), COPD (48.8% vs 8.5%), and AF (1.9% vs 1.1%) than did the non-bronchiectasis cohort ([Table 1](#t1-copd-12-1375){ref-type="table"}). The patients with bronchiectasis had a significantly lower prevalence of being not comorbid with any medical disorders when compared with the patients without bronchiectasis (28.9% vs 48.7%, *P*\<0.001).

Comparison of incidence and risk of ischemic stroke stratified by sex, age, and comorbidity between bronchiectasis and non-bronchiectasis patients
--------------------------------------------------------------------------------------------------------------------------------------------------

As indicated in [Table 2](#t2-copd-12-1375){ref-type="table"}, the patients with bronchiectasis exhibited a higher incidence rate of ischemic stroke (9.18 vs 4.66 per 1,000 PYs) than those without bronchiectasis with a crude HR of 1.93 (95% CI =1.43--2.61) and an adjusted HR (aHR) of 1.74 (95% CI =1.28--2.35) after controlling for age, sex, and comorbidities. The incidence rates of ischemic stroke increased with age in both cohorts. After adjusting for covariates, the risk of stroke was higher in the middle-aged patients (aHR =4.79, 95% CI =1.88--12.17) and elderly patients (aHR =11.76, 95% CI =4.76--29.07) compared to the younger patients. The risk of ischemic stroke was significantly higher in the bronchiectasis cohort than those in non-bronchiectasis cohort in both sexes (crude HR =1.98, 95% CI =1.32--2.97 for men and crude HR =1.89, 95% CI =1.21--2.96 for women). After adjusting for covariates, the risk of stroke was not significantly different in both sexes despite men exhibiting higher incidence of ischemic stroke than women.

Comparison of incidence and HR of ischemic stroke by individual comorbidity between bronchiectasis and non-bronchiectasis patients
----------------------------------------------------------------------------------------------------------------------------------

The patients with bronchiectasis had a higher incidence of stroke than did the patients without bronchiectasis regardless of comorbidities. The incidence of stroke was higher in patients with one or more comorbidities, including hypertension, diabetes, hyperlipidemia, CAD, CHF, COPD, and AF, compared with the patients without the corresponding comorbidity. However, after adjustment for covariates, hypertension, diabetes, and AF remained independent risk factors of stroke development ([Table 3](#t3-copd-12-1375){ref-type="table"}).

Joint effect of bronchiectasis and comorbidity on the risk of ischemic stroke
-----------------------------------------------------------------------------

[Table 4](#t4-copd-12-1375){ref-type="table"} lists the joint effect of bronchiectasis and individual comorbidity on the risk of ischemic stroke. Patients with bronchiectasis comorbid with diabetes, AF, or hypertension exhibited a multiplicative risk of ischemic stroke compared with patients with neither bronchiectasis nor comorbidity. The odds ratios of ischemic stroke associated with bronchiectasis and covariates, including sex, age, and comorbidity, are shown in [Table 5](#t5-copd-12-1375){ref-type="table"}. Patients with bronchiectasis, older age, or other comorbidity had significantly higher risk of ischemic stroke.

Association of risk of ischemic stroke and number of emergency department visits and hospitalizations in patients with bronchiectasis
-------------------------------------------------------------------------------------------------------------------------------------

[Table 6](#t6-copd-12-1375){ref-type="table"} presents the incidence and risk of ischemic stroke in patients without bronchiectasis and patients with bronchiectasis based on the number of emergency department visits and hospitalizations a year. The risk of ischemic stroke in patients with bronchiectasis increased with the annual number of emergency department visits and hospitalizations (aHR =4.31, 95% CI =2.53--7.35 for 1--3 times/year; aHR =6.24, 95% CI =2.30--16.89 for \>3 times/year) compared with those without bronchiectasis.

Cumulative probability of ischemic stroke between patients with and without bronchiectasis during follow-up periods
-------------------------------------------------------------------------------------------------------------------

[Figure 1](#f1-copd-12-1375){ref-type="fig"} illustrated that the cumulative probability of ischemic stroke was significantly higher in the bronchiectasis cohort than in the comparison cohort (log-rank test, *P*\<0.001).

Discussion, limitations, and conclusion
=======================================

This longitudinal cohort study demonstrated that the incidence of ischemic infarction was higher in the bronchiectasis cohort than in the non-bronchiectasis cohort (9.18 vs 4.66 per 1,000 PYs). The patients with bronchiectasis exhibited a significantly (*P*\<0.05) higher prevalence of CAD, CHF, COPD, and AF than did the patients without bronchiectasis, which is consistent to previous studies.[@b15-copd-12-1375]--[@b19-copd-12-1375] After adjustment for sex, age, and comorbid disorders, the bronchiectasis cohort had a 1.74-fold increased risk of developing ischemic stroke compared with the non-bronchiectasis cohort. Similarly, Navaratnam et al[@b6-copd-12-1375] also reported that people with bronchiectasis exhibited a 1.92-fold higher risk of stroke compared with those without bronchiectasis. However, in contrast to our study, they used a cross-sectional design rather than the cohort study to evaluate the prevalence of stroke in patients with bronchiectasis.[@b6-copd-12-1375]

The possible mechanisms for the increased risk of ischemic stroke need further elucidation. Bronchiectasis is characterized by chronic inflammation and inability to clear airway secretion, which results in recurrent infection. Previous studies have reported that patients with bronchiectasis are related to increased systemic inflammation.[@b26-copd-12-1375],[@b27-copd-12-1375] Inflammation also plays a pivotal role in the initiation and progression of atherosclerosis[@b28-copd-12-1375] and is associated with vulnerable atherosclerotic plaque and subsequent thromboembolic events.[@b29-copd-12-1375],[@b30-copd-12-1375] The vulnerable atheromatous plaque in carotid arteries is responsible for acute ischemic stroke.[@b31-copd-12-1375] In addition, observational studies have demonstrated that acute respiratory tract infections like influenza and *Chlamydia pneumoniae* infection are associated with the increased incidence and risk of stroke.[@b32-copd-12-1375]--[@b36-copd-12-1375]

The bronchiectasis cohort exhibited higher incidence of ischemic stroke than did the non-bronchiectasis cohort irrespective of sex, age subgroups, and comorbidity. Most patients with bronchiectasis were women (54.8%), a finding which is consistent with previous studies.[@b37-copd-12-1375],[@b38-copd-12-1375] The incidence of stroke increased with age. As presented in this study, 78.3% (173/221) of ischemic stroke occurred in elderly adults, which is consistent with previous reports.[@b39-copd-12-1375],[@b40-copd-12-1375] Compared to the young adults, middle-aged and elderly adults had 4.79- and 11.76-fold increased risks of stroke development, respectively. As evident in a previous study, the elderly have a high incidence of carotid artery stenosis, which is a major risk factor of ischemic stroke.[@b41-copd-12-1375] In addition, watershed stroke is more common in the elderly adults than in the young adults, which is associated with the fact that the elderly have a higher prevalence of AF, hypertension, cardiovascular dysfunction, and other medical disorders.[@b40-copd-12-1375],[@b42-copd-12-1375]--[@b44-copd-12-1375]

Hypertension, diabetes, and AF remained the independent risk factors of stroke development in the bronchiectasis and non-bronchiectasis cohorts. Bronchiectasis combined with diabetes, AF, or hypertension exhibited a multiplicative risk of ischemic stroke ([Table 3](#t3-copd-12-1375){ref-type="table"}). Furthermore, regarding COPD, the incidence rate of stroke was significantly higher in bronchiectasis patients without COPD than in non-bronchiectasis patients without COPD (7.31 vs 4.27 per 1,000 PYs) ([Table 3](#t3-copd-12-1375){ref-type="table"}). Although not significant, the incidence rate of stroke was also higher in bronchiectasis patients with COPD than in non-bronchiectasis patients with COPD (11.20 vs 8.53 per 1,000 PYs). The bronchiectasis cohort still carried a 1.74-fold increased risk of developing ischemic stroke compared with the non-bronchiectasis cohort after adjustment for covariates, despite 50% of the bronchiectasis cohort having COPD in our dataset.

Furthermore, symptom overlap between COPD and bronchiectasis may complicate discriminative diagnoses of these two diseases. As evident in this study, among the patients with bronchiectasis, up to 48.8% also had COPD ([Table 1](#t1-copd-12-1375){ref-type="table"}). A similar observation was reported in previous studies that bronchiectasis coexisted in 30%--57% of patients with COPD,[@b45-copd-12-1375]--[@b48-copd-12-1375] which significantly increased the duration of ICU stay and hospital admission[@b46-copd-12-1375] as well as the mortality rate.[@b4-copd-12-1375],[@b48-copd-12-1375] On the other hand, a Germany study showed that, with bronchiectasis as the primary diagnosis, 39% of the hospitalized patients were found to be comorbid with COPD and emphysema.[@b49-copd-12-1375] COPD and bronchiectasis share many features in common, presenting a similar inflammatory profile with symptoms of chronic cough and sputum production, and both sometimes overlap, complicating their discriminative diagnoses and treatments.[@b50-copd-12-1375] Bronchiectasis is generally diagnosed with the presence of airway dilation and airway wall thickness based on HRCT examination, whereas COPD is diagnosed based on the manifestation of poorly reversible airflow obstruction, symptoms of shortness of breath, and exposure to cigarette smoke and pollutants.[@b50-copd-12-1375] However, according to a UK study, some COPD patients also exhibited airway wall abnormality, while 81% of patients diagnosed with bronchiectasis were current smokers or had a history of smoking.[@b45-copd-12-1375] Moreover, a recent study confirmed airway wall abnormality, typically manifested in bronchiectasis, in patients with COPD exacerbation.[@b48-copd-12-1375] High prevalence rate and great severity of bronchiectasis presented in COPD patients suggested bronchiectasis as a pathological phenotype of COPD, which may have prognostic and therapeutic implications.[@b51-copd-12-1375]

Patients with bronchiectasis who had respiratory infection-related ED visits and hospitalization exhibited a dose--response effect on the risk of ischemic stroke. The finding may explain the relationship of severity of bronchiectasis and frequent respiratory infections with an increased risk of developing stroke.

Several limitations should be addressed in the current study. First, the detailed smoking habits and physical activity levels are not available in the LHID. Hypertension and COPD are well-recognized comorbidities associated with cigarette smoking.[@b52-copd-12-1375],[@b53-copd-12-1375] Therefore, we controlled for hypertension and COPD to mediate the influence of smoking. Second, although diagnoses based on ICD-9-CM codes may cause misclassification, we used HRCT to help validate the diagnosis of bronchiectasis and ischemic stroke. Furthermore, the NHIA routinely audits the claims data through an administrative and peer-review process to minimize medical fraud.

The strength of our study is that it is a large population-based sample: this is the first study on Asian people to evaluate the incidence and risk of ischemic stroke in patients with bronchiectasis. All NHI beneficiaries are assigned personal identification numbers that facilitate follow-up of the study patients.

In conclusion, this cohort study of 1,295 patients (6,312.70 PYs) with bronchiectasis and 6,475 patients (34,958.00 PYs) without bronchiectasis demonstrated that bronchiectasis patients carried a 1.74-fold increased risk of ischemic stroke compared with those without bronchiectasis. Patients with bronchiectasis experiencing frequent respiratory infections are at a substantial risk of ischemic stroke. Clinicians should take proactive strategy to carefully assess risk factors of stroke and holistically treat patients with bronchiectasis.
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###### 

Demographic characteristics and comorbidity in patients with and without bronchiectasis

  Variable                                                     Bronchiectasis   *P*-value     
  ------------------------------------------------------------ ---------------- ------------- ---------
  Sex, n (%)                                                                                  1
   Female                                                      3,550 (54.8)     710 (54.8)    
   Male                                                        2,925 (45.2)     585 (45.2)    
  Age, mean (SD)[a](#tfn2-copd-12-1375){ref-type="table-fn"}   62.0 (15.3)      62.0 (15.3)   1
  Age stratification, n (%)                                                                   1
   \<50 years                                                  1,445 (22.3)     289 (22.3)    
   50--64 years                                                2,075 (32.0)     415 (32.0)    
   ≥65 years                                                   2,955 (45.6)     591 (45.6)    
  Comorbidity, n (%)                                                                          
   Hypertension                                                2,399 (37.1)     476 (36.8)    0.842
   Diabetes                                                    1,018 (15.7)     208 (16.1)    0.759
   Hyperlipidemia                                              986 (15.2)       171 (13.2)    0.62
   CAD                                                         849 (13.1)       217 (16.8)    0.001
   CHF                                                         181 (2.8)        103 (8.0)     \<0.001
   COPD                                                        553 (8.5)        632 (48.8)    \<0.001
   AF                                                          73 (1.1)         25 (1.9)      0.018
   Without any comorbidity                                     3,151 (48.7)     374 (28.9)    \<0.001

**Notes:** *χ*^2^ test;

Student's two sample *t*-test.

**Abbreviations:** SD, standard deviation; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.

###### 

Comparison of incidence and hazard ratio of ischemic stroke stratified by sex, age, and comorbidity between patients with and without bronchiectasis

  Variables                                                 Bronchiectasis   Crude HR[b](#tfn5-copd-12-1375){ref-type="table-fn"} (95% CI)   aHR[c](#tfn6-copd-12-1375){ref-type="table-fn"} (95% CI)                                                                                                 
  --------------------------------------------------------- ---------------- --------------------------------------------------------------- ---------------------------------------------------------- ---- ---------- ------- --------------------------------------------------------------------- -----------------------------------------------------------------------
  All                                                       163              34,958.00                                                       4.66                                                       58   6,312.70   9.18    1.93 (1.43--2.61)[\*\*\*](#tfn10-copd-12-1375){ref-type="table-fn"}   1.74 (1.28--2.35)[\*\*\*](#tfn10-copd-12-1375){ref-type="table-fn"}
  Sex                                                                                                                                                                                                                                                                                                 
   Female                                                   73               19,220.60                                                       3.80                                                       26   3,559.90   7.30    1.89 (1.21--2.96)[\*](#tfn8-copd-12-1375){ref-type="table-fn"}        1
   Male                                                     90               15,737.40                                                       5.72                                                       32   2,752.80   11.62   1.98 (1.32--2.97)[\*\*](#tfn9-copd-12-1375){ref-type="table-fn"}      1.31 (0.99--1.70)
  Age stratification, years                                                                                                                                                                                                                                                                           
   \<50                                                     4                8,040.40                                                        0.50                                                       1    1,548.20   0.65    1.29 (0.14--11.57)                                                    1
   50--64                                                   34               11,290.80                                                       3.01                                                       9    2,098.10   4.29    1.42 (0.68--2.96)                                                     4.79 (1.88--12.17)[\*\*](#tfn9-copd-12-1375){ref-type="table-fn"}
   ≥65                                                      125              15,626.80                                                       7.99                                                       48   2,666.40   18.0    2.18 (1.56--3.04)[\*\*\*](#tfn10-copd-12-1375){ref-type="table-fn"}   11.76 (4.76--29.07)[\*\*\*](#tfn10-copd-12-1375){ref-type="table-fn"}
  Comorbidity[d](#tfn7-copd-12-1375){ref-type="table-fn"}                                                                                                                                                                                                                                             
   No                                                       34               17,260.50                                                       1.97                                                       4    1,970.30   2.03    1.02 (0.36--2.88)                                                     1
   Yes                                                      129              17,697.50                                                       7.29                                                       54   4,342.40   12.43   1.66 (1.21--2.28)[\*\*](#tfn9-copd-12-1375){ref-type="table-fn"}      2.66 (1.85--3.84)[\*\*\*](#tfn10-copd-12-1375){ref-type="table-fn"}

**Notes:**

Incidence rate per 1,000 PYs;

relative hazard ratio;

multivariable analysis including age, sex, and comorbidities;

only have one of the comorbidities: hypertension, diabetes, hyperlipidemia, CAD, CHF, COPD, and AF.

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001.

**Abbreviations:** HR, hazard ratio; aHR, adjusted HR; CI, confidence interval; PYs, person-years; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.

###### 

Comparison of incidence and HR of ischemic stroke between patients with and without bronchiectasis by considering individual comorbidities

  Variables        Bronchiectasis   Crude HR[b](#tfn13-copd-12-1375){ref-type="table-fn"} (95% CI)   aHR[c](#tfn14-copd-12-1375){ref-type="table-fn"} (95% CI)                                                                                                 
  ---------------- ---------------- ---------------------------------------------------------------- ----------------------------------------------------------- ---- ---------- ------- --------------------------------------------------------------------- ---------------------------------------------------------------------
  Hypertension                                                                                                                                                                                                                                                 
   No              63               22,409.60                                                        2.81                                                        18   4,179.70   4.31    1.52 (0.90--2.57)                                                     1
   Yes             100              12,548.40                                                        7.97                                                        40   2,133.00   18.75   2.27 (1.57--3.27)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1.62 (1.21--2.17)[\*\*](#tfn16-copd-12-1375){ref-type="table-fn"}
  Diabetes                                                                                                                                                                                                                                                     
   No              107              29,613.70                                                        3.61                                                        38   5,331.50   7.12    1.94 (1.34--2.81)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1
   Yes             56               5,344.30                                                         10.47                                                       20   981.20     21.02   1.90 (1.14--3.17)[\*](#tfn15-copd-12-1375){ref-type="table-fn"}       1.97 (1.47--2.65)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}
  Hyperlipidemia                                                                                                                                                                                                                                               
   No              132              29,857.40                                                        4.42                                                        46   5,545.20   8.29    1.84 (1.31--2.57)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1
   Yes             31               5,100.60                                                         6.07                                                        12   767.50     15.63   2.55 (1.31--4.98)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   0.88 (0.62--1.62)
  CAD                                                                                                                                                                                                                                                          
   No              120              30,369.50                                                        3.95                                                        38   5,337.50   7.12    1.77 (1.23--2.56)[\*](#tfn15-copd-12-1375){ref-type="table-fn"}       1
   Yes             43               4,588.50                                                         9.37                                                        20   975.20     22.55   2.08 (1.22--3.55)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1.34 (0.98--1.83)
  CHF                                                                                                                                                                                                                                                          
   No              152              33,980.90                                                        4.47                                                        49   5,888.30   8.32    1.83 (1.32--2.52)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1
   Yes             11               977.10                                                           11.25                                                       9    424.40     21.22   1.79 (0.73--4.34)                                                     1.17 (0.72--1.91)
  COPD                                                                                                                                                                                                                                                         
   No              136              31,793.20                                                        4.27                                                        24   3,278.70   7.31    1.68 (1.09--2.60)[\*\*](#tfn16-copd-12-1375){ref-type="table-fn"}     1
   Yes             27               3,164.80                                                         8.53                                                        34   3,034.0    11.20   1.23 (0.74--2.05)                                                     1.14 (0.81--1.59)
  AF                                                                                                                                                                                                                                                           
   No              158              34,589.70                                                        4.56                                                        52   6,202.10   8.38    1.80 (1.31--2.46)[\*\*\*](#tfn17-copd-12-1375){ref-type="table-fn"}   1
   Yes             5                368.30                                                           13.57                                                       6    110.60     54.24   3.84 (1.17--12.62)[\*](#tfn15-copd-12-1375){ref-type="table-fn"}      1.92 (1.02--3.61)[\*](#tfn15-copd-12-1375){ref-type="table-fn"}

**Notes:**

Incidence rate per 1,000 person-years;

relative hazard ratio;

multivariable analysis including age, sex, hypertension, diabetes, hyperlipidemia, CAD, COPD, AF, and bronchiectasis.

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001.

**Abbreviations:** HR, hazard ratio; aHR, adjusted HR; CI, confidence interval; PYs, person-years; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.

###### 

Cox proportional hazard regression analysis for the risk of ischemic stroke associated with the joint effect of bronchiectasis and individual comorbidity

  -------------------------------------------------------------------------------------------------------------------------------
  Variables                               N       Event n   aHR[a](#tfn19-copd-12-1375){ref-type="table-fn"}\
                                                            (95% CI)
  -------------------- ------------------ ------- --------- ---------------------------------------------------------------------
  **Bronchiectasis**   **Diabetes**                         

  No                   No                 5,457   107       1

  Yes                  No                 1,087   38        2.00 (1.38--2.90)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  No                   Yes                1,018   56        2.20 (1.59--3.05)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  Yes                  Yes                208     20        4.42 (2.74--7.14)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  **Bronchiectasis**   **AF**                               

  No                   No                 6,402   158       1

  Yes                  No                 1,270   52        1.88 (1.37--2.57)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  No                   Yes                73      5         1.89 (0.77--4.61)

  Yes                  Yes                25      6         7.02 (3.10--15.9)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  **Bronchiectasis**   **Hypertension**                     

  No                   No                 4,076   63        1

  Yes                  No                 819     18        1.61 (0.95--2.72)

  No                   Yes                2,399   100       1.79 (1.30--2.47)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}

  Yes                  Yes                476     40        4.02 (2.69--6.02)[\*\*\*](#tfn20-copd-12-1375){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Multivariable analysis including age and sex;

*P*\<0.001.

**Abbreviations:** aHR, adjusted hazard ratio; CI, confidence interval; AF, atrial fibrillation.

###### 

Odds ratios of ischemic stroke associated with bronchiectasis and covariates

  Variable                                                   Crude odds ratio (95% CI)                                               Adjusted odds ratio[a](#tfn22-copd-12-1375){ref-type="table-fn"} (95% CI)
  ---------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------
  Bronchiectasis                                                                                                                     
   No                                                        1                                                                       1
   Yes                                                       1.82 (1.34--2.47)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}     1.62 (1.19--2.22)[\*\*](#tfn24-copd-12-1375){ref-type="table-fn"}
  Sex                                                                                                                                
   Female                                                    1                                                                       1
   Male                                                      1.51 (1.16--1.98)[\*\*](#tfn24-copd-12-1375){ref-type="table-fn"}       1.3 (0.99--1.71)
  Age stratification, years                                                                                                          
   \<50                                                      1                                                                       1
   50--64                                                    6.08 (2.40--12.70)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}    4.75 (1.86--12.09)[\*\*](#tfn24-copd-12-1375){ref-type="table-fn"}
   ≥65                                                       17.74 (7.28--43.23)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}   11.5 (4.63--28.5)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}
  Comorbidity[b](#tfn23-copd-12-1375){ref-type="table-fn"}                                                                           
   No                                                        1                                                                       1
   Yes                                                       4.13 (2.91--5.88)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}     2.29 (1.59--3.31)[\*\*\*](#tfn25-copd-12-1375){ref-type="table-fn"}

**Notes:**

Multivariable analysis including bronchiectasis, age, sex, and comorbidities;

only have one of the comorbidities: hypertension, diabetes, hyperlipidemia, CAD, CHF, COPD, and AF.

*P*\<0.01 and

*P*\<0.001.

**Abbreviations:** CI, confidence interval; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.

###### 

Comparison of ischemic stroke risk between bronchiectasis and comparison cohorts by annual number of emergency room visits and hospitalization due to acute respiratory infection

                                       Ischemic stroke   HR (95% CI)                                                           
  -------------------- --------------- ----------------- --------------------------------------------------------------------- ----------------------------------------------------------------------
  Non-bronchiectasis                   163/6,475         1 (Reference)                                                         1 (Reference)
  Bronchiectasis                                                                                                               
   \<1                                 39/1,128          1.44 (1.01--2.04)                                                     1.37 (0.96--1.95)
   1--3                                15/136            6.45 (3.80--11.0)[\*\*\*](#tfn28-copd-12-1375){ref-type="table-fn"}   4.31 (2.53--7.35)[\*\*\*](#tfn28-copd-12-1375){ref-type="table-fn"}
   \>3                                 4/31              8.13 (3.01--22.0)[\*\*\*](#tfn28-copd-12-1375){ref-type="table-fn"}   6.24 (2.30--16.89)[\*\*\*](#tfn28-copd-12-1375){ref-type="table-fn"}
                       *P* for trend                     \<0.001                                                               \<0.001

**Notes:**

Multivariable analysis including age, sex, and comorbidities.

*P*\<0.001.

**Abbreviations:** HR, hazard ratio; CI, confidence interval.

[^1]: These authors contributed equally to this work
